Cardiovascular Systems — Q2 FY2020 Earnings Presentation
8 slides from Cardiovascular Systems's earnings presentation, Feb 5, 2020
Slide 1: Q2 FY20 Earnings Call February 5, 2020
Q2 FY20 Earnings Call February 5, 2020
Slide 2: Safe Harbor: Forward Looking Statements
Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem
Slide 3: Q2 Worldwide Revenues of $68.3 Million
Q2 Worldwide Revenues of $68.3 Million 13.5% Increase in Revenue ($ in millions) Revenues US Coronary grew 22% Drivers US Peripheral grew 9% 14% unit growth Launch of full line of Drivers US support products 12% unit growth Peripheral, US Coronary, 21% OBL revenue growth $47.5 $18.5 4% hospital reve
Slide 4: Financial Results
Q2 FY20 Financial Results ($ in millions) Worldwide Peripheral Revenue Growth Worldwide Coronary Revenue Growth $48.3 $47.6 $45.5 $20.0 $20.8 $44.2 $45.2 $19.0 $18.2 8% $16.0 30% growth growth in Q2 in Q2 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 Q2 FY20 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 Q2 FY20 Gross Margin Ca
Slide 5: Highlights
Q2 FY20 Highlights Financial Operational - Peripheral Operational – Coronary Other Revenue Growth +13.5% vs. LY • Strong case support drove • Growing adoption of coronary • Sold >22,500 OAS units strength in hospitals and office toolkit featuring OAS with • Certified 66 international Gross Margin 79
Slide 6: Key Events & Milestones
Key Events & Milestones FY19A FY20E FY21E Sold 80,650 OAS WIRION acquisition • Hemodynamic support - First in Human International revenue = $7.9M LIBERTY 360 3-Year Data • International revenue = $15-$17.5M Launched OAS in SE Asia, Europe • Launch OAS in up to 10 new countries • Launch OAS in Canada
Slide 7: FY20 Guidance (as of 2-5-20)
FY20 Guidance (as of 2-5-20) For fiscal 2020 ending June 30, 2020, CSI anticipates: • Revenue of $280 million to $283 million, representing 13% to 14% growth compared with fiscal 2019; • Gross profit margin of 79% to 80%; • Net loss of approximately 2% of revenues, including approximately $1 million
Slide 8: Investor Contact
Investor Contact: Jack Nielsen 651-202-4919 j.nielsen@csi360.com CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire®, WIRION® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2019 Cardiovascular Systems, Inc. CSII OrbusNeich®, Teleport® and Sapphire® are trademarks
Cardiovascular Systems — Q2 FY2020 Earnings Presentation on 6ix